Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.

Core Viewpoint - Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims against P3 Health Partners, Inc. regarding potential violations of federal securities laws due to misleading statements made by the company and its executives [1][2]. Summary by Relevant Sections Allegations and Investigation Focus - The investigation aims to determine if P3 Health Partners and its officers made false or misleading statements that violated federal securities laws [1]. Triggering Events - On November 12, 2024, P3 reported disappointing financial results, including a negative adjusted EBITDA of $15 million due to a write-down of midyear risk adjustment receivables, and an additional $10 million in expenses from negative medical claims developments. The company also incurred another $10 million in network and operating expenses. As a result, the stock price plummeted from $19.50 to $10.45, marking a decline of 46.4% within two days [2][5]. - On March 28, 2025, P3 disclosed in its annual Form 10-K that it received a civil investigative demand from the Department of Justice regarding its marketing practices and remuneration for Medicare Advantage brokers and related parties [5].